Scarica l'app Stockscreener
55.81
0.79%
0.44
Dopo l'orario di chiusura:
55.56
-0.25
-0.45%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EXEL Giù?
Forum
Previsione
Exelixis Inc Borsa (EXEL) Ultime notizie
Exelixis Inc (EXEL) Income Statement - TradingKey
Exelixis Inc (EXEL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Exelixis Inc (EXEL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Exelixis, Inc. Revenue Breakdown – BX:EX9 - TradingView
Exelixis Inc (EXEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Exelixis Inc (EXEL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Exelixis, Inc. Revenue Breakdown – LSX:936718 - TradingView
EXEL|Exelixis Inc|Price:55.370|Chg%:-0.280 - TradingKey
EXELIXIS INC EXELIXIS ORD SHS (0IJO.L) Q1 FY2026 earnings call transcript - Yahoo Finance
Exelixis Inc (EXEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
EXEL Maintained by Morgan Stanley -- Price Target Raised to $53 - GuruFocus
EXEL stock trades steadily as Exelixis leans on expanding oncology revenue - Ad-hoc-news.de
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026 - BioSpace
What Happened at Exelixis (NASDAQ:EXEL) Before Results Date? - Kalkine Media
Exelixis to release Q2 2026 financial results on August 5 - scanx.trade
Lobbying Update: $560,000 of EXELIXIS INC. lobbying was just disclosed - Quiver Quantitative
Exelixis (EXEL) earnings expected to grow: Should you buy? - MSN
Exelixis (EXEL) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
(EXEL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
What's Driving Exelixis' Recent Momentum and 2026 Outlook - Kavout | AI
Exelixis (EXEL) Stock May Be Undervalued Following FDA Review Uncertainty - simplywall.st
EXEL Maintained by Barclays -- Price Target Raised to $49 - GuruFocus
Analysts Conflicted on These Healthcare Names: Exelixis (EXEL) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Exelixis, Inc. (EXEL) hit a 52-week high, can the run continue? - MSN
Daily Brief Industrials: Archion, Baycurrent, easyJet PLC, Hanjin KAL Corp, World-Link Logistics (Asia), Genneia, Robotechnik Intelligent Te-A, Shenzhen Megmeet Electrical , Exelixis Inc, Rush Enterprises Inc Cl A and more - Smartkarma
Daily Brief Health Care: Apnimed, Cigna Group, Exelixis Inc, Scribe Therapeutics, CSPC Pharmaceutical and more - Smartkarma
Daily Brief Financials: SBI Funds Management Ltd, Choice International, Kotak Mahindra Bank, Exelixis Inc, Bank Mandiri Persero, Ryan Specialty Holdings and more - Smartkarma
symbol__ Stock Quote Price and Forecast - CNN
EXEL Maintained by Wells Fargo -- Price Target Raised to $49.00 - GuruFocus
Exelixis, Inc. (EXEL) Stock Analysis: Navigating Growth In The Oncology Biotech Space - DirectorsTalk Interviews
Is Exelixis (EXEL) Expensive After Its Recent Rally Or Still Undervalued? - Yahoo Finance
Exelixis (EXEL) Stock Trades At A Discount After Its 236% Run - Yahoo Finance
EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth? - Yahoo Finance
Exelixis Announces Zanzalintinib in Combinati - Moomoo
Exelixis: STELLAR-303 Results Mixed, STELLAR-304 Success Likely (NASDAQ:EXEL) - Seeking Alpha
Is Exelixis, Inc. (EXEL) Among the Best Under-the-Radar Stocks to Invest In? - Yahoo Finance
Handa, Intas Face Patent Suits Over Exelixis Cancer Drug - Law360
Exelixis focuses on oncology pipeline as Nasdaq-listed biotech pursues growth - ad-hoc-news.de
Exelixis, Inc. (EXEL) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June - AOL.com
Axsome Therapeutics, Exelixis, Incyte Among 20 New Stocks On IBD's Premier Watchlists - Investor's Business Daily
EXEL Maintained by RBC Capital -- Price Target Raised to $46.00 - GuruFocus
Exelixis Inc stock hits all-time high at 56.22 USD - Investing.com
Exelixis Inc stock hits all-time high at 56.22 USD By Investing.com - Investing.com Nigeria
Truist Financial Maintains Exelixis(EXEL.US) With Hold Rating, Raises Target Price to $56 - Moomoo
RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating - marketscreener.com
Exelixis, Inc. (EXEL) Stock Analysis: A Biotech Powerhouse with Strong Revenue Growth and High Analyst Interest - DirectorsTalk Interviews
Zanzalintinib Trial Outcomes And Index Exit Might Change The Case For Investing In Exelixis (EXEL) - simplywall.st
ETFs Investing in Exelixis, Inc. Stocks - TradingView
Price to sales forward of Exelixis, Inc. – NASDAQ:EXEL - TradingView
Exelixis, Inc. (EXEL) Stock Price Today - CoinMarketCap
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Santhera Pharmaceuticals Holding (OtherSPHDF) - The Globe and Mail
Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says - marketscreener.com
UBS raises Exelixis stock price target to $52 on pipeline outlook - Investing.com Nigeria
UBS Adjusts Price Target on Exelixis to $52 From $43, Maintains Neutral Rating - marketscreener.com
EXEL Reiterated by HC Wainwright & Co. -- Price Target Maintained at $56 - GuruFocus
H.C. Wainwright reiterates Exelixis stock rating at Buy, $56 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Exelixis stock rating at Buy, $56 target - Investing.com
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):